Early gains for generics in Cymbalta patent expiry: Sources

31-12-2013 Moneycontrol.comComments (0)

CymbaltaEli LillyPharmaceutical

The recent patent expiry of Eli Lily's depression drug Cymbalta has meant some early gains for a few Indian generic drug firms. The 5.5 billion dollar drug Cymbalta lost patent protection on December 12 and opened doors for generic competition. And it ...

Read more on Moneycontrol.com

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top